A Phase 1 Study To Investigate the Pharmacokinetics of SR Formulations; and the Food Effect, Safety, Tolerance, Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020 In Young Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 31 May 2014
At a glance
- Drugs Centanafadine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- Sponsors Neurovance
- 04 Feb 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Sep 2013 Planned End Date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov record.
- 21 Feb 2013 Status changed from not yet recruiting to recruiting, as reported in a Neurovance media release.